BEHAVE-AD

BEHAVE-AD

Behavioral Pathology in Alzheimer's Disease Rating Scale. A neurological testing instrument used to assess patients with Alzheimer’s disease, which provides a global rating of non-cognitive symptoms. It is used to benchmark the efficacy of clinical drugs.
References in periodicals archive ?
At a dose of about 1 mg/day, risperidone also has significantly greater efficacy than haloperidol (Haldol) as shown by results of BEHAVE-AD and CMAI--beginning around week 4-6 of treatment--in two trials of treatment for agitation and aggression in patients with dementia (Neurology 1999;53:946-55, Am.
At a dose of about 1 mg per day, risperidone also has significantly greater efficacy than haloperidol (Haldol) as shown by results of BEHAVE-AD and CMAI--beginning around week 4-6 of treatment--in two trials of treatment for agitation and aggression in patients with dementia (Neurology 1999;53:946-55; Am.
Patients who scored above 0 for wandering on the BEHAVE-AD scale had a hazard ratio of 0.